Biomarker: PD-L2

Histology type: endometrial carcinoma

Stage: advanced stage

Country: Turkey

Region: Ankara

Study type: retrospective cohort study

Followed up time :

Conclusion: PD-1, PD-L1, and PD-L2 may be a potential target for immunotherapy in elderly and advanced stage EC patients.

Sample type : tissue

Sample method: immunohistochemistry

Expression pattern : positive(total score>2)

Expression elevation: Cytoplasmic and membranous staining of PD-1, PDL1, PD-L2 in tumor and immune cells was accepted as positive.evaluated the combined proportion and intensity. The proportion was scored as: 0, none; <1/100, 1; 1/100 to 1/10, 2; 1/10 to 1/3, 3; 1/3 to 2/3, 4; and >2/3, 5. The intensity was scored as: none, 0; mild, 1; moderate, 2; and strong, 3 . The overall scores (Allred scores) were the sum of the proportion score and intensity score for each patient (range, 0; or from 2 to 8, respectively). The scores were reclassified as “negative” for a total score ≤2 (staining <1% or mild staining),“low” for scores 3 to 4, and “high” for a score ≥5.

Statictics: Mean (SD);Range

Cohort age: 62.9 ± 11.9;35–89

Funtion Uniprot: Involved in the costimulatory signal, essential for T-cell proliferation and IFNG production in a PDCD1-independent manner. Interaction with PDCD1 inhibits T-cell proliferation by blocking cell cycle progression and cytokine production (By similarity)

UniProt ID: Q9BQ51

UniProt Link: https://www.uniprot.org/uniprotkb/Q9BQ51/entry

Biological function from UniProt: Adaptive immunity, Immunity

Molecular function from UniProt:

Tissue specificity from UniProt: Highly expressed in heart, placenta, pancreas, lung and liver and weakly expressed in spleen, lymph nodes and thymus.

Subcellular UniProt: #Cell membrane #Membrane #Secreted

Alternative name from UniProt:

Gene name from HGNC: PDCD1LG2 (B7-DC, bA574F11.2, Btdc, CD273, PD-L2, PDL2)

CD antigen name: CD273

Induction: Up-regulated by IFNG/IFN-gamma stimulation in monocytes and induced on dendritic cells grown from peripheral blood mononuclear cells with CSF2 and IL4/interleukin-4.

HPA link: https://www.proteinatlas.org/ENSG00000120217-CD274

Tissue specificity RNA from HPA: Tissue enhanced (lymphoid tissue)

Tissue expression from HPA: Cytoplasmic expression at variable levels in all tissues.

Subcellular summary HPA Located in Cytosol

Cancer prognostic summary HPA Prognostic marker in renal cancer (unfavorable)

Pathology link: https://www.proteinatlas.org/ENSG00000197646-PDCD1LG2/pathology

Pathology endo: https://www.proteinatlas.org/ENSG00000197646-PDCD1LG2/pathology/endometrial+cancer

OMIM: 605723

OMIM link2: https://www.omim.org/entry/605723

HGNC ID: HGNC:18731

HGNC link: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:18731